Weakened role for Brazilian medicines agency in granting patents is not enough, says industry
This article was originally published in Scrip
Executive Summary
Brazil's R&D-based industry association, Interfarma, has welcomed a controversial legal decision to restrict the powers of medicines regulator ANVISA in the granting of patents. Nevertheless, it says the move did not go far enough. Meanwhile, civil society groups claim the decision is a setback for public health and are taking their case to the United Nations.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.